

SCIENTIFIC PROGRAM

SEPTEMBER, 8TH

17:45 18:30	SPDM Nutrition Group Meeting
19:00 19:45	Welcome drink

SEPTEMBER, 9TH

08:30	Registration opening
09:15	Symposium Opening
09:30 10:30	Session I - IEM's mapping
09:30 10:00	MetabERN - where are we now? <i>Maurizio Scarpa, IT</i>
10:00 10:30	Broadening the concept of IMD: Novel disorders and international classification <i>Carlos Ferreira, USA</i>
10:30 11:00	Coffee break
11:00 13:00	Session II - Newborn Screening for IEM
11:00 11:30	Newborn Screening in Europe and initiatives to develop programmes in low - and middle-income countries <i>Jim Bonham, UK</i>
11:30 12:00	New tests and future directions in the NBS for IEM <i>Giancarlo LaMarca, IT</i>
12:00 12:30	Treatment follow-up of screened disorders <i>Paula Garcia, PT</i>
12:30 13:00	Oral Communications to the table
13:00 14:00	Lunch / Poster view
14:00 15:50	Session III - From Cbl to Hcy
14:00 14:30	Remethylation disorders: from cobalamin absorption, intracellular pathways to MTHFR deficiency <i>Matthias Baumgartner, CH</i>
14:30 15:00	Inherited disorders of transsulfuration: clinical presentation, diagnosis, and recent advances in therapy? <i>Viktor Kozich, CZ</i>
15:00 15:30	The transsulfuration pathway at the crossroads between homocysteine and hydrogen sulfide metabolism: (dys)regulation and (patho)physiological implications <i>João Vicente, PT</i>
15:30 15:50	Oral communications to the table
15:50 16:20	Coffee break
16:20 17:20	Session IV - IEM Nutritional and Pharmacological treatment
16:20 16:50	Current and future approaches in PKU treatment <i>Cary Harding, USA</i>
16:50 17:20	Micronutrients – role in IEM treatment <i>Júlio César Rocha, PT</i>
17:20 18:00	Session V - General Oral communications
18:00 19:30	Thematic Meeting - PKU Breaking the Dogma - (Programme page 11)
20:30 21:45	Symposium dinner

SEPTEMBER, 10TH

09:00 10:30	Session VI - The acetyl-CoA cross
09:00 09:30	Pyruvate dehydrogenase complex deficiency in Portugal: the clinical, metabolic, and mutational landscapes and its peculiar characteristics <i>Hana Pavlu-Pereira, PT</i>
09:30 10:00	Ketotic glycogen storage diseases (GSD): current knowledge, management, and monitoring <i>Ulrike Steuerwald, DE</i>
10:00 10:30	How to find your way through metabolic disorder in patients with rhabdomyolysis <i>Pascal Laforêt, FR</i>
10:30 11:00	Coffe break
11:00 13:00	Session VII - Lysosomal Disorders
11:00 11:30	A new face in the diagnosis and monitoring of lysosomal disorders <i>Johannes Aerts, NL</i>
11:30 12:00	Gene therapy for lysosomal storage disorders: advances, challenges and perspectives. <i>Maria José Castro, ES</i>
12:00 12:30	Immunomodulation and ERTs <i>Simon Jones, UK</i>
12:30 13:00	Oral Communications to the table
13:00 14:00	Lunch / Poster view
14:00 15:30	Session VIII - The ammonia roundabout
14:00 14:30	New insights into the pathophysiology and molecular basis of UCD's <i>Johannes Haberle, CH</i>
14:30 15:00	Potential role of gene therapy for OTC deficiency <i>Alvaro Hermida, ES</i>
15:00 15:30	A novel small molecule approach for the treatment of propionic and methylmalonic acidemias <i>Marshall Summar, USA</i>
15:30 16:00	Coffee break
16:00 17:30	Session IX - Down Town Mitochondria
16:00 16:30	Mitochondrial plasticity - role in muscle pathology <i>Rita Ferreira, PT</i>
16:30 17:00	Renal involvement in Mitochondrial Disorders <i>Margarida Coelho, PT</i>
17:00 17:30	The diagnosis of mitochondrial disease using multi-omic methodologies <i>Charlotte Alston, UK</i>
17:30 17:45	Bolsa SPDM Dr Aguinaldo Cabral 2019 <i>Sandra Alves, PT</i>
17:45	Awards / Closing remarks

09TH SEPTEMBER 2021

ORAL COMMUNICATIONS

12h30 – 13h00 | Session II – **Newborn Screening for IEM**

OC 01	When the newborn screening prevents ketoacidosis, <i>J Tenete, Vila Nova de Gaia, PT</i>
OC 02	Trifunctional protein deficiency – case report of neonatal onset, <i>M Rodrigues, Porto, PT</i>
OC 03	Carnitine uptake deficiency in asymptomatic patients – the importance of 5' untranslated region (UTR) of SLC22A5, <i>H Santos, Vila Nova de Gaia, PT</i>

15h30 - 15h50 | Session III – **From CbL to Hcy**

OC 04	A Case Series of Paediatric Classical Homocystinuria – nutritional status, dietary intake and metabolic profile, <i>RS Loureiro, Lisboa, PT</i>
OC 05	New predictives for low vitamin B12 in newborns, <i>P Lipari Pinto, Lisboa, PT</i>

17h20 | 18h00 | Session V – **General Oral Communications**

OC 09	Long-term, sustained efficacy and safety results from a phase 1/2 clinical trial of an AAV8-mediated liver-directed gene therapy in adults with glycogen storage disease type Ia, <i>Maria-Luz C Pico, Santiago de Compostela, SP</i>
OC 10	AAV8 Gene Therapy as a Potential Treatment in Adults with Late-Onset Ornithine Transcarbamylase (OTC) Deficiency: Updated Results From a Phase 1/2 Clinical Trial, <i>Maria-Luz C Pico, Santiago de Compostela, SP</i>
OC 11	Genotypic and phenotypic features of the mothers of children with mtDNA-associated Leigh syndrome, <i>CA Soares, Porto, PT</i>
OC 12	New causes of persistent or recurrent 3-methylglutaconic aciduria – expanding the differential diagnosis of secondary 3-MGA-uria, <i>F Freitas, Porto, PT</i>

10TH SEPTEMBER 2021

ORAL COMMUNICATIONS

12h30 - 13h00 | Session VII – **Lysosomal Disorders**

OC 06	Targeted RNA-based therapies for Mucopolysaccharidosis, <i>Jl Santos, Porto, PT</i>
OC 07	Functional characterization of five novel mutations found in patients with suspicion of Fabry disease, <i>P Varela-Calais, São Paulo, BR</i>
OC 08	NIEMANN PICK Type C – 26 years of diagnosis in a Portuguese Reference Center, <i>AM Capela, Porto, PT</i>